Stock Surge Following Analyst Rating#
Immunic Inc. (NASDAQ: IMUX) experienced a notable increase in its stock price, rising 7.7% on Tuesday. This uptick followed a new coverage initiation by Guggenheim analyst Yatin Suneja, who assigned a Buy rating to the stock along with a price target of $7.00.
Promising Therapy for Multiple Sclerosis#
The company is focused on developing vidofludimus calcium, an oral treatment for multiple sclerosis (MS). This therapy aims to help patients with both relapse-associated worsening and progression of the disease, regardless of relapse activity. MS is a chronic illness that affects the central nervous system, leading to various neurological symptoms.
Positive Study Results#
Analyst Yatin Suneja pointed out that vidofludimus calcium has shown encouraging results in two Phase II clinical trials. These studies involved 268 patients with relapsing MS and 467 patients with progressive MS. The results indicated a reduction in relapse risks and better control of disability. Importantly, the drug maintained a safety profile similar to a placebo, meaning it did not show significant side effects like liver toxicity or the need for extensive monitoring.
Future Expectations#
Looking ahead, Guggenheim anticipates that positive topline data from the Phase III ENSURE study for relapsing MS will be available by the end of 2026, involving approximately 1,100 patients. Additionally, a Phase III readout for primary progressive MS is expected around 2030. The analyst estimates that peak global sales could reach about $1 billion for relapsing MS and around $2 billion for primary progressive MS, with varying probabilities of success. Currently, Immunic's market capitalization stands at roughly $800 million.